DCC Regulatory & Policy Update 05/26
- hans.au
- vor 10 Stunden
- 11 Min. Lesezeit
June 2026
Contents
Severing the Hukou Link: Social Insurance Delinked from Household Registration
Foreign Investment & Market Access
The New Outbound Investment Regulations
Competition & Market Regulation
Where the Subsidy War Went: SAMR Sustains the Anti-"Involution" Campaign
China Pulls the Trigger: MOFCOM Invokes the Blocking Rules for the First Time
ECONOMICS & MACRO-REGULATION
Severing the Hukou Link: Social Insurance Delinked from Household Registration
On 22 May 2026, the State Council publicly released the Implementation Opinions on Providing Basic Public Services in Places of Habitual Residence (关于推行常住地提供基本公共服务的实施意见), under which restrictions tying participation in employee social insurance to local household registration ("hukou", 户口) will be fully lifted.
What is Hukou?
In simple terms, hukou is a household registration system tying Chinese citizens to a locality (usually inherited from parents). It has long determined access to education, healthcare, and social services based on where your hukou is located rather than where you live and is often seen as a draconian method of controlling population movements in China. For example, 10 years ago it was very difficult to get better medical treatment in a big Chinese city if your hukou was on the country-side, often resulting in families selling off property and borrowing money to receive privately paid treatment. Hukou restrictions have eased in smaller cities but remain significant in megacities. The system is undergoing reform to accommodate rapid urbanization and a quickly aging society in China.
Severing the Hukou Link: Social Insurance Delinked from Household Registration
The Guidelines instruct cities to remove hukou-based barriers to workplace social-insurance enrolment, allowing workers to participate in social-insurance programmes in the city where they are employed, regardless of their place of registration. Alongside the insurance change, the Guidelines call for strengthened basic medical coverage and employment services for long-term residents holding temporary residence permits, improved access to compulsory-education school places for migrant children, expansion of public rental housing to non-registered residents in stable employment, and the gradual extension of local services such as elderly care, social assistance and disability support. Authorities are also directed to refine the mechanisms for transferring and continuing social-insurance relationships across regions.
Why It Matters
Employers with migrant, blue-collar or gig/platform workforces face social-insurance enrolment obligations in the city of employment that the hukou link previously allowed many to avoid in practice. For platform operators and labour-intensive businesses in particular, this is a direct cost and a workforce-classification question rolled into one: where contribution duties previously fell away because workers were registered elsewhere, they now attach at the place of work.
What to Watch
Employer’s contributions to added social security. Given the growing financial pressure due to the demographics of a rapidly aging Chinese society and a slowing economy, employers will be increasingly called to bear social security costs, whether it is migrational employment or long-term care insurance scheme (Update 03/26)
Contribution mechanics and rates. The Guidelines set no national contribution formula; watch for the per-city contribution base, rate and employer/employee split as local rules emerge.
Enrolment triggers for gig and platform workers. The single largest ambiguity is what constitutes "stable employment" and which platform-worker arrangements cross the enrolment threshold. This is where classification risk concentrates.
City-by-city rollout timing. The Guidelines set no reform schedule and leave the pace to local governments; tier-1 cities with rationed hukou (Beijing, Shanghai) are likely to move differently from lower-tier cities, so monitor sequencing rather than expecting a single national switch.
Since the cost impact here compounds with other social-contribution changes, please contact us if you would like help modelling the combined exposure across your China footprint.
Foreign Investment & Market Access
The New Outbound Investment Regulations
On 17 April 2026 the State Council adopted the Regulations of the State Council on Outbound Investment (国务院关于对外投资的规定, "ODI Regulations"), which take effect on 1 July 2026. This is the first administrative regulation (行政法规) to comprehensively govern outbound direct investment ("ODI") by Chinese investors; the full "life cycle" of investment outside of China. The ODI Regulations consolidate the previously separate National Development and Reform Commission ("NDRC") and Ministry of Commerce ("MOFCOM") frameworks under a single instrument, producing a more unified and more enforceable compliance architecture. The official Q&A, jointly run by the Ministry of Justice, NDRC and MOFCOM on 1 June 2026, states plainly that governance "principally on the basis of departmental rules and normative documents" (部门规章、规范性文件) no longer meets current needs given geopolitical risk and intensifying international competition.
Key Provisions
Articles 10 to 12 of the ODI Regulations retain the existing classification of investments — encouraged, restricted and prohibited — and preserve the core approval-and-filing regime, but now embed continuous information-reporting obligations and clearer authority for regulators to intervene at any stage of an investment's life cycle. Article 13 identifies three standalone channels through which controlled technology may be transferred and thereby regulated: direct export; transfer through personnel deployment; and cross-border licensing — capturing technology transfers even without an equity component. Article 15 of the ODI Regulations introduces an outbound investment security review ("OISR"): NDRC and MOFCOM, with other State Council departments, may review outbound investments that "affect or may affect national security" — deliberately broad language reaching initial investments as well as post-investment asset transfers and disposals. In substance, the three categories of activity now expressly in scope are (i) offshore restructurings — what practitioners have begun to call the "Singapore Wash" (a must-read is the Manus case in Update 04/26); (ii) technology transfer via licensing or personnel without equity; and (iii) disposals of existing overseas assets. The enforcement toolkit includes orders to unwind investments and significant monetary penalties, and the regime newly brings individual investors within scope.
Why It Matters
For foreign businesses, the most important point is counterparty-facing: this is, on its face, a regulation directed only at Chinese outbound investors. But its risk does transmit across the deal table. Foreign joint-venture partners and acquirers of Chinese-linked assets (which now could include a cross-border technology and IP transfer contract) inherit and are rather significantly impacted by their counterparty's compliance exposure. In practice, we have seen problems ranging from time losses due to the Chinese party having to do a re-filing, growth limitations when the Chinese JV-party is unable to inject additional equity or debt beyond the filed or approved ODI scope, or limitations in sales due to restricted geographical scope or narrowly defined to-market avenues in the ODI document. Extensive due diligence is needed to understand the perimeter in which the Chinese JV-party is allowed to move.
What to Watch
Implementing rules and catalogues. The ODI Regulations do not yet specify the controlled technologies or sectors; watch for the implementing measures and any sector list. Based on existing transfer-control practice, AI, semiconductors, critical minerals, EV batteries and certain biotechnologies are the likely early focus.
The first Article 15 OISR reviews. No designations or countermeasures had been activated as of promulgation. The first concrete security review will set the practical reach of the regime far more than the text does.
National economic security and export control. The ODI Regulations are a part of the recent economic security and export control drive of Chinese regulators – see our Decree 834 and Decree 835 post – and extends it to the outbound investment area. Affected counterparts of Chinese offshore businesses should therefore maintain a keen interest in the whole area of economic security and sanctions of the Chinese government.
The policies and local approval practices regarding ODI is highly dynamic and the counterparty-risk dimension is, in our experience, almost always heavily underestimated; please contact us if you have transactions or are engaged in a JV that may be exposed.
Competition & Market Regulation
Where the Subsidy War Went: SAMR Sustains the Anti-"Involution" Campaign
Through May 2026, the State Administration for Market Regulation ("SAMR") has continued to press its campaign against "involution-style" competition (内卷, neijuan) in the platform economy. This is an update on the food-delivery price war, on which we reported first in Update 03/26. The subsidy wars (补贴大战) refer to the aggressive price battles among big tech — primarily Meituan, Alibaba's Ele.me (now Taobao Flash) and JD.com — which spent tens of billions of RMB subsidizing large consumer discounts (e.g., meals and coffee for 1 RMB) and rider incentives to aggressively capture market share.
The Campaign in Context
The Anti-Unfair Competition Law ("AUCL"), the third revision of the law adopted by the Standing Committee of the National People's Congress on 27 June 2025, effective 15 October 2025, prohibits platform operators from forcing merchants to sell below cost, bars large enterprises from abusing an "advantageous position" against small and medium-sized enterprises ("SMEs"), and specifically addresses involution-style competition conducted through data, algorithms and platform rules.
As detailed in our Update 03/26, Beijing had signalled by March 2026 that its patience with the food-delivery subsidy war was running out, following repeated SAMR warnings and escalation to a State Council inter-ministerial antitrust committee.
Enforcement has hardened over time: already in January 2026 SAMR had published its top-ten "typical cases" of rectifying involution-style competition for 2025 and, alongside the NDRC and the Supreme People's Court, issued administrative guidance and warnings. When platforms responded by redirecting their marketing spend away from price subsidies to algorithmic pricing, platform-rule design and merchant-facing terms, SAMR shifted toward a catch-all "competition ecology" approach. SAMR is now prioritising SME survival and fair market returns over headline low prices — most recently reflected in its May 2026 34-point private-sector work plan – but is also making clear that they want the platform economies as a whole to be healthy and fair.
Why It Matters
For big tech platform companies, the practical message is that scaling down an overt subsidy mechanism does not avoid regulatory exposure if the competitive spend simply reappears in another guise but with the same effect to "kill off" competitors. The enforcement lens is now the effect on the competitive ecosystem, not merely the form of the discount. Companies in thin-margin platform sectors well beyond food delivery should assume the campaign's logic applies to them and re-examine pricing algorithms, subsidy structures and merchant agreements accordingly.
What to Watch
Breadth of the "involution" concept. Keep an eye on how far SAMR will rein in other thin-margin platform sectors (e-commerce, logistics, ride-hailing, instant retail) beyond the delivery sector.
Finalisation of the Internet Platform Antitrust Compliance Guidelines (draft, November 2025), expected to formalise obligations around algorithm transparency and fair dealing for platform operators.
No big tech at the cost of ordinary folks ("lao bai xing"). Since several years Chinese regulators stepped in against big tech companies — ed-tech 2021, fin tech/Alibaba 2020-2023, ride hailing/Didi 2021-2023 — when excessive platform power was used at the expense of basic services and its beneficiaries (low-wage workers, consumers). This major trend will continue.
Technology & Health
A New Compliance Architecture for Pharma: The Revised Drug Administration Law Implementing Regulation (Decree No. 828)
The revised Regulations for the Implementation of the Drug Administration Law ("Decree No. 828") were issued by the State Council on 27 January 2026 and became effective on 15 May 2026. This is a sector-specific development particularly relevant for pharmaceutical and biotech businesses in 2026.
Key Changes
The revision introduces a dedicated chapter centred on the Marketing Authorization Holder ("MAH"), placing lifecycle accountability on the MAH. MAHs must maintain a comprehensive quality system, establish an independent quality-management department, and designate a production lead, a quality lead and a "quality authorised person" responsible for independent batch release, together with a pharmacovigilance system aligned with Good Pharmacovigilance Practices. The revision also does the following:
Expands exclusivity. Formal market exclusivity is expanded up to two years for eligible new pediatric medicines and up to seven years for eligible orphan drugs (the latter contingent on the MAH guaranteeing supply, and terminating early if supply obligations are not met); data exclusivity is expanded up to six years for the undisclosed trial data of drugs with novel chemical entities.
Enables contract and segmented manufacturing under tighter oversight, and permits certain post-approval sales of pre-approval commercial-scale batches.
Links post-market evaluation to re-registration, so that lifecycle performance feeds directly into the right to remain on the market.
Addresses overseas data and online sales. Article 10 of Decree No. 828 provides for acceptance of qualifying overseas research data; online platforms must operate quality-management systems and verify participants, while high-risk products (vaccines, blood products, narcotics, psychotropic and toxic drugs, radioactive drugs and precursor chemicals) are barred from online sale.
Why It Matters
For multinational pharma and biotech, the practical consequence is that China operations can no longer be run as a self-contained local regulatory function: MAH governance — quality systems, named responsible persons, pharmacovigilance, supply guarantees tied to exclusivity — now demands enterprise-wide integration with global quality and compliance structures. The exclusivity provisions are a genuine inducement to bring innovative and orphan products to the China market, but they come bundled with continuing obligations that carry their own forfeiture risk. The linkage of post-market evaluation to re-registration is the clearest expression of the "full lifecycle" philosophy, which is currently a general regulatory trend.
What to Watch
Acceptance standards for overseas clinical evidence. Article 10 Decree No. 828 opens the door in principle; watch the National Medical Products Administration's ("NMPA") implementing standards for how readily overseas data is accepted in practice. Expect multi-jurisdiction data compliance work to keep several departments busy.
How exclusivity is applied in practice. Watch the first pediatric and orphan-drug exclusivity grants, and in particular how the supply-guarantee condition is enforced and what will trigger early termination.
Segmented and contract manufacturing oversight. Watch the supervisory expectations attached to segmented manufacturing, which will determine how usable the new flexibility actually is.
Sanctions & Economic Security
China Pulls the Trigger: MOFCOM Invokes the Blocking Rules for the First Time
On 2 May 2026, MOFCOM issued Announcement No. 21 of 2026 (商务部公告2026年第21号 公布关于美国对5家中国企业实施涉伊朗石油制裁措施的阻断禁令), a prohibition order under the Rules on Counteracting Unjustified Extraterritorial Application of Foreign Legislation and Other Measures, issued by MOFCOM (Order No. 1 of 2021) on 9 January 2021, effective upon promulgation on the same date ("Blocking Rules"). It is the first time China has used the Blocking Rules in the five years since they entered into force. This is precisely the operational follow-through we flagged as "what to watch" after Decrees No. 834 and No. 835 in Update 04/26 — the latent counter-sanctions tools moving from passive deterrent to live activation.
What the Order Does.
The Blocking Order prohibits Chinese citizens, legal persons and organisations from recognising, enforcing or complying with specified United States sanctions imposed on five Chinese petrochemical companies — the "teapot" refineries Hengli Petrochemical (Dalian) Refining Co., Ltd., Shandong Shouguang Luqing Petrochemical Co., Ltd., Shandong Jincheng Petrochemical Group Co., Ltd., Hebei Xinhai Chemical Group Co., Ltd., and Shandong Shengxing Chemical Co., Ltd. The U.S. Treasury's Office of Foreign Assets Control ("OFAC") had added these firms to the Specially Designated Nationals ("SDN") List on 24 April 2026, under Executive Orders 13902 and 13846, over alleged Iranian-oil transactions. MOFCOM, following a working-mechanism assessment, concluded that the measures constitute an improper extraterritorial application of foreign law.
Why It Matters
A tension that was previously theoretical is now a live conflict of laws. Companies running global sanctions-compliance policies face a direct bind: complying with the U.S. sanctions on these five entities may itself breach Chinese law. The exposure is sharpest for Chinese subsidiaries of foreign multinationals and for counterparties of the refineries that sit between the two regimes. Ceasing dealings with a blocked entity to satisfy OFAC, without first seeking a MOFCOM exemption, can expose the Chinese subsidiary to Chinese administrative penalties and to private civil litigation under the Blocking Rules. The episode is also a caution against reflexive over-compliance: blanket worldwide blocking of every SDN-listed entity, common in multinational programmes, is now itself a source of Chinese legal risk where the designation is one China has chosen to block.
What to Watch
The fate of OFAC General Licence V. Watch whether OFAC extends, replaces or lets the licence lapse at its 24 May 2026 wind-down deadline; if it lapses without relief, the compliance conflict becomes immediate.
Enforcement of non-compliance penalties. No enforcement action has yet tested the Order; watch the first penalty or Article 12 civil claim for how aggressively Beijing intends to enforce.
The exemption pathway. Watch how MOFCOM operates the exemption-application mechanism in practice — its accessibility will largely determine whether multinationals can manage the conflict or are simply caught by it.
Given the genuine conflict-of-laws exposure here — particularly for clients with Chinese subsidiaries inside global sanctions programmes — please contact legal counsel before adjusting any China-facing compliance posture.
© DCC Consulting | dcc.consulting
Kommentare